

Lab on a Chip

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

A smartphone platform for the quantification of vitamin D levels

Seoho Lee¹, Vlad Oncescu¹, Matt Mancuso², Saurabh Mehta³, David Erickson^{1*}

Abstract

1 Vitamin D deficiency has been linked to a number of diseases and adverse outcomes including:
2 osteoporosis, infections, diabetes, cardiovascular diseases, and even cancer. At present the vast majority
3 of vitamin D testing is performed in large-scale laboratories at the request of a physician as part of an
4 annual panel of blood tests. Here we present a system for rapid quantification of vitamin D levels on a
5 smartphone. The system consists of a smartphone accessory, an app, and a test strip that allows the
6 colorimetric detection of 25-hydroxyvitamin D using a novel gold nanoparticle-based immunoassay. We
7 show that the system can be used to accurately measure physiological levels of 25-hydroxyvitamin D with
8 accuracy better than 15nM and a precision of 10nM. We compare our system with well-established
9 ELISA test kits for serum samples of unknown concentration and demonstrate equivalency of the results.
10 We envision this as the first step towards the development of the NutriPhone, a comprehensive system for
11 the analysis of multiple vitamins and micronutrients on a smartphone.

¹ Sibley School of Mechanical and Aerospace Engineering, Cornell University, Ithaca, NY 14853, USA

² Department of Biomedical Engineering, Cornell University, Ithaca, NY 14853, USA

³ Division of Nutritional Sciences, Cornell University, Ithaca, NY 14853, USA

*de54@cornell.edu

Introduction

1 Vitamin D deficiency is prevalent worldwide¹ and has been linked to diabetes², cardiovascular diseases^{3,4},
2 infections^{5,6}, and cancer^{7,8} in addition to bone diseases such as osteoporosis⁹ and rickets¹⁰. Deficiency is
3 commonly defined in humans by measuring serum concentrations of 25-hydroxyvitamin D, or 25(OH)D,
4 the circulating form of vitamin D. The currently recommended cutoffs for vitamin D deficiency and
5 insufficiency are defined by 25(OH)D levels below 50nM and 80nM respectively. Low levels of vitamin
6 D can usually be improved by consuming supplements and increasing skin exposure to sunlight.¹¹
7 However, many people are unaware of their vitamin D status due to the lack of simple methods for
8 diagnosing and tracking 25(OH)D concentrations in the blood. The ability to monitor vitamin D levels
9 may help those at risk to detect low levels at an earlier stage and enable corrective interventions before
10 the occurrence of potentially irreversible damage. Reliance on supplements alone without knowledge of
11 true vitamin D status may fall short in addressing severe vitamin D deficiencies (<20nM) or in some cases
12 lead to possible vitamin D intoxication.^{11, 12} At present, most 25(OH)D tests are conducted using high-
13 performance liquid chromatography (HPLC), liquid chromatography-tandem mass spectrometry (LC-
14 MS) techniques, or certain immunoassays such as radioimmunoassay (RIA) and enzyme-linked
15 immunosorbent assay (ELISA).¹³⁻¹⁵ These methods are time consuming, costly and difficult to perform in
16 most settings outside sophisticated laboratories. Recently, a lateral flow assay for vitamin D (Test4D;
17 Nanospeed Diagnostics) has been introduced¹⁶, demonstrating the commercial need for such rapid, point-
18 of-care vitamin D analysis. Smartphone based diagnostics offer additional advantages over lateral flow
19 assays including the abilities to quantify results, track changes with time, and provide user-free error
20 tracking.

21 We present here the vitaAID – *vitamin AuNP*-based *Immunoassay Device* – a system for rapid
22 quantification of vitamin D levels on a smartphone. This is achieved through the development of: a
23 smartphone accessory, app, and novel gold nanoparticle (AuNP) based colorimetric competitive direct-
24 antigen immunoassay. This assay enables us to quantify 25(OH)D molecules whose small size
25 (~400g/mol) restricts their binding to more than one antibody at a time.^{17, 18} Gold nanoparticle based
26 colorimetric assays^{19, 20} coupled with smartphone technology have previously been used for the
27 quantification of mercury contamination in water samples as demonstrated by Wei *et al.*²¹ In addition,
28 smartphone platforms were used for the detection of biomarkers in complex bodily fluids²²⁻²⁵, thereby
29 demonstrating the ability to do rapid, personalized diagnostics.

30 In this paper we describe the vitaAID and show how 25(OH)D levels can be quantified by evaluating
31 brightness differences between the detection area and a reference area on the vitaAID test strip. We then
32 demonstrate that the vitaAID system can be used to quantify vitamin D levels by evaluating serum
33 samples with unknown 25(OH)D concentrations and comparing the results to those obtained using a
34 commercial ELISA method.

Results

1 **vitaAID system and test strip surface chemistry.** The vitaAID system consists of a smartphone
2 accessory and custom test strip as shown in Fig. 1a. The accessory has been designed to minimize the
3 effect of variability in external lighting conditions with a 5mm amber LED ($\lambda=592\text{nm}$) embedded in a
4 polydimethylsiloxane (PDMS) diffuser used to illuminate the back of the test strip. The test strip is
5 composed of a detection area and reference area. The reference area allows the algorithm to further adjust
6 to differences in smartphone cameras. The detection area that enables the colorimetric reaction to occur
7 consists of a surface-immobilized layer of 25(OH)D. There is currently no standard method for obtaining
8 a chemically stable coating layer of 25(OH)D due to the small size and absence of linkable functional
9 groups on the 25(OH)D. We addressed this by developing a novel 25(OH)D coating process onto a fused
10 Si-based substrate that serves as the detection area on the test strip. As shown in Fig. 1b, we coated the 3-
11 aminopropyltriethoxysilane (APTES) and polystyrene-*co*-maleic anhydride (PSMA) layers sequentially
12 on a fused Si substrate and covalently linked aminopropylated 25(OH)D to achieve a stable 25(OH)D
13 coating. In order to validate this method, the surface treatments were characterized by Fourier-transform
14 infrared spectroscopy (FT-IR) as shown in Fig. 1b. The initial introduction of APTES layer on the Si
15 substrate is evident from the transmittance peak at 1654cm^{-1} that is associated with primary amine groups
16 ($-\text{NH}_2$).²⁶ The PSMA coating is confirmed by the appearance of peaks at 1850 and 1780cm^{-1} which have
17 been linked with maleic anhydrides in other studies.²⁶⁻²⁸ Lastly, the peak at 3300cm^{-1} corresponds to the
18 formation of the secondary amine (R_2NH) bond between the PSMA and aminopropylated 25(OH)D and
19 verifies the 25(OH)D immobilization.²⁹

1 **Surface-based gold nanoparticle immunoassay.** The colorimetric reaction on the detection area of the
2 test strip is based on a novel surface-based gold nanoparticle-based immunoassay as shown in Fig. 2a.
3 When a sample is applied onto the detection area of the test strip, only the antibody conjugates that are
4 not bound to the 25(OH)D present in the initial sample are captured by the coated 25(OH)D on the
5 surface. The colorimetric signals from the immobilized AuNP-antibody conjugates are then amplified

6 using a silver enhancement scheme as the silver ions undergo reduction on the surface of the AuNP to
7 increase their size and thereby increase the sensitivity of the system. For samples with high vitamin D
8 levels, most of the antibody conjugates are occupied with 25(OH)D from the initial sample, resulting in
9 only a subtle change in the colorimetric signal on the test strip. For samples with low vitamin D levels,
10 the test strip develops an intense color that reflects the high number of antibody conjugates bound on the
11 surface. The steps involved in the preparation of the AuNP-anti-25(OH)D conjugate solution and the
12 detection area are discussed in the Methods section.

13 A critical step during testing is the incubation of the AuNP-anti-25(OH)D sample solution on the test
14 strip's detection area. It is important to characterize the time it takes for the AuNP-anti-25(OH)D to
15 immobilize in order to minimize the total assay time and to improve accuracy. In Fig. 2b ,we show the
16 effect of different incubation times on the brightness difference between the detection and reference areas
17 of the test strip (ΔH) for a sample without 25(OH)D. After 6h the brightness difference is within 10% of
18 that obtained after a typical 12h overnight incubation. This indicates that a 6h incubation time is sufficient
19 in order to obtain accurate results during such vitamin D measurements. The incubation time can however
20 be significantly reduced by using the obtained negative exponential relationship to determine the
21 minimum incubation time for ensuring that sufficient conjugate binding events have occurred on the
22 detection area. In a recent study, Kai *et al.*³⁰ have demonstrated that the incorporation of microfluidic
23 channels could further reduce such incubation times to the order of minutes through improved binding
24 kinetics.

1 **Quantification of colorimetric reaction.** Once the competitive binding of AuNP-anti-25(OH)D was
2 performed on the test strip, the quantification of the 25(OH)D levels in the initial sample can be achieved
3 using the vitaAID smartphone platform. First, the colorimetric change is captured using the smartphone's
4 camera after inserting the test strip in the vitaAID accessory. In Fig. 3a we show the colorimetric change
5 in the transparent fused silica detection region at different known concentrations of 25(OH)D and the
6 colorimetric change on the white reference region due to changes in exposure time of the camera. The
7 iPhone automatically adjusts its camera exposure times in response to the amount of light passing through
8 the detection region. Therefore, by comparing the differences in brightness between the detection area
9 (B_{det}) and reference area (B_{ref}) we can estimate the concentration of 25(OH)D independent of the exposure
10 setting of the iPhone camera. In Fig. 3b we show that $\Delta H = B_{\text{det}} - B_{\text{ref}}$ can be correlated to the 25(OH)D
11 concentration in the initial sample. A second order polynomial was then fitted onto this calibration curve
12 in order to obtain a function such that $[25(\text{OH})\text{D}] = f(\Delta H)$.

13 Fig. 3c shows the algorithm that allows the quantification of 25(OH)D across the entire range of
14 physiological values. First, the detection area is scanned for silver enhanced regions where AuNP-anti-
15 25(OH)D is bound. This is important because at higher 25(OH)D concentrations in the initial sample, the
16 detection area rarely exhibits a uniform colorimetric change. A 100px by 100px area around the high
17 intensity silver enhanced region is taken and the brightness is averaged across all the pixels in that area.
18 The brightness is a coordinate in the Hue Saturation Brightness (HSB) color model and is computed from
19 the Red Green Blue (RGB) average values as described elsewhere.³¹ The same steps are then performed
20 on the reference region and an average brightness is calculated. Once the brightness difference between
21 the detection area and the reference area is computed, the algorithm uses a second order polynomial
22 $[25(\text{OH})\text{D}] = f(\Delta H)$ derived from Fig. 3b to calculate the 25(OH)D concentration in the initial sample.

1
1 **Accuracy and precision compared to ELISA.** The accuracy of the vitaAID system was characterized by
2 quantifying 25(OH)D levels in solutions of known concentrations and comparing them to results obtained
3 using a commercial ELISA kit. In Fig. 4a we show variations in predicted 25(OH)D levels for 3 standard
4 solutions of 15nM, 40nM and 110nM. At each concentration, 3 test strips were used and the maximum
5 error across all the samples and concentrations was measured as 14.1nM at a concentration of 40nM. The
6 maximum average inter-sample difference was 9.8nM also at 40nM. These errors are of the same order as
7 those of ELISA methods for the quantification of 25(OH)D levels.

8 In Fig. 4b, 3 serum samples of unknown 25(OH)D concentration are evaluated using both the vitaAID
9 system and an ELISA method. As indicated previously, 25(OH)D levels below 50nM indicate vitamin D
10 deficiency while level below 20nM indicate a severe deficiency. Both methods are in agreement that 2 of
11 the samples are 25(OH)D deficient, while the other is borderline deficient. Moreover, 2 of the ELISA
12 measurements fall within the range of values measured using the vitaAID system and one is within 2nM
13 of that range.

Discussion

1 In this paper we presented the vitaAID system which allows for the fast and accurate quantification of
2 25(OH)D levels. This system uses a novel gold nanoparticle-based immunoassay in order to produce a
3 surface colorimetric reaction that can be quantified directly on a smartphone. We have demonstrated that
4 we can measure physiological levels of 25(OH)D in solution with accuracy better than 15nM and a
5 precision of 10nM. Moreover we show that the results obtained using the vitaAID system are comparable

6 with that of commercial ELISA kits. By analyzing 3 serum samples with unknown 25(OH)D
7 concentration we were able to determine accurately the extent of vitamin D deficiency in each case. These
8 results represent a promising step in the development of an accurate system for determining vitamin D
9 levels which has many potential applications as a point-of-care tool both in the developed and the
10 developing world.

11 In the future, this method for vitamin D quantification can be further improved in terms of precision and
12 accuracy. Here, we used a specific form of 25(OH)D for coating and detection, namely 25(OH)D₃ and
13 anti-25(OH)D₃. The monoclonal anti-25(OH)D₃ has 68% cross reactivity with 25(OH)D₂ and 100% with
14 25(OH)D₃. The use of 25(OH)D₃ for the detection zone coating allows for the capturing of all the
15 unbound AuNP-anti-25(OH)D₃ conjugates after the initial interaction with the sample. Nonetheless, this
16 difference in the antibody affinity inevitably causes our method to underestimate the total 25(OH)D level
17 which is the sum of the 25(OH)D₂ and 25(OH)D₃ levels. This represents the shortcoming of most
18 immunoassays for vitamin D (e.g. ELISA kit; Alpcos, radioimmunoassay; DiaSorin) as demonstrated
19 through clinical comparison studies with other detection standards such as HPLC and LC-MS.^{13, 14, 32}

Methods

1 **Sample preparation.** For a vitamin D deficiency test, once the sample has been acquired, several steps
2 are performed in solution prior to its application onto the vitaAID test strip. First, the filtered serum
3 sample is mixed 1:10 (v/v) with 0.78g/ml acetonitrile (Thermo Fisher Scientific Inc.) in order to liberate
4 the 25(OH)D molecules that are in proportion of 95-99% bound to vitamin D binding proteins (DBP).^{33, 34}
5 The sample is then mixed with AuNP-anti-25(OH)D conjugate solution for 30min. This ensures that all
6 the 25(OH)D initially present in the blood sample is bound to AuNP-anti-25(OH)D before being applied
7 onto the test strip.

1 **AuNP-anti-25(OH)D₃ conjugate preparation.** The spherical AuNP (Nanopartz Inc., 30nm) came pre-
2 treated with N-hydroxysuccinimide ester terminal (NHS) groups which specifically reacted with the
3 primary amines of monoclonal anti-25(OH)D₃ IgG (Raybiotech Inc.) to form the AuNP-antibody
4 conjugates. The antibody was first purified using the Pierce Antibody Clean-up Kit (Thermo Fisher
5 Scientific Inc.) because 2% bovine serum albumin (BSA) stabilizers in anti-25(OH)D₃ are known to
6 interfere with the amine-reactive conjugation.³⁵ The antibody solution was placed into the Melon Gel-
7 based purification support which binds non-antibody proteins while allowing the IgG antibody to flow

8 through in a purified form during the one-minute centrifugation at 6000g. The successful removal of BSA
9 was checked by performing sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). For
10 conjugation, the AuNP were mixed with the purified anti-25(OH)D₃ at 0.1mg/ml in 0.01M amine-free
11 phosphate buffer saline (PBS) buffer at pH 7.4. The mixture was sonicated for 30s to re-suspend AuNP
12 into solution, followed by vortexing for 30min at room temperature.³⁶ The centrifugation was performed
13 at 15000g for 10min to remove the excess antibody in supernatant form and the final conjugates were
14 reconstituted in 0.01M PBS with 0.1% Tween-20 at pH 7.4. The successful conjugation was confirmed
15 through surface plasmon resonance changes using ultraviolet-visible spectroscopy. The conjugates were
16 diluted to 10μg/ml and stored at 4°C until use.

1 **Detection area preparation.** The covalent immobilization of 25(OH)D was achieved by obtaining
2 25(OH)D₃, 3'-Aminopropyl Ether (Toronto Research Chemicals Inc.) and using its primary amines as
3 linkers to the test strip surface. Immobilization of the peptides to surface using maleic anhydride
4 chemistry has been demonstrated previously by others.^{37, 38} Here, the aminopropylated 25(OH)D₃ was
5 immobilized on a flat Si substrate other than on a typical well-plate which represents a compatibility
6 improvement for use in our smartphone-based detection. Briefly, 4" fused Si wafers were cleaned in
7 piranha solution, immersed in 20mM APTES (Sigma-Aldrich Co. LLC) in isopropanol for 2h and
8 annealed at 120°C for 1h. The APTES coating acted as an activation layer for the binding of 1% PSMA
9 (Sigma-Aldrich Co. LLC) dissolved in tetrahydrofuron, which was spin-coated at 3500rpm for 30s
10 followed by curing at 120°C for 2h. The treated Si wafer was cooled and immersed in acetone for 10min
11 and subsequently diced into 4 by 7mm strips. Finally, the 25(OH)D immobilization was achieved by
12 incubating the PSMA-treated strips with 20μg/ml aminopropylated 25(OH)D₃ in the coating buffer (0.1M
13 carbonate/bicarbonate buffer at pH 9.4) for 1h at 37°C. The unreacted PSMA sites were treated by
14 incubating the blocking buffer (0.01M PBS with 1mg/ml Casein and 0.05% Kathon preservative at pH
15 7.4) for 30min at room temperature, and cleaned with washing buffer (0.01M PBS with 0.05% Tween-20
16 at pH 7.4). The incubation procedures were performed in custom incubation chambers that housed the test
17 strips and prevented pre-mature drying of the treatment solutions. The modified Si surfaces after each
18 surface treatment were characterized by FT-IR using a Vertex 80-v spectrometer (Bruker Optics)
19 equipped with a 60° germanium attenuated total reflection (VeeMax Ge ATR) crystal. For each spectrum,
20 256 scans at a spectral resolution of 4cm⁻¹ were performed using a liquid nitrogen detector. After the 6h
21 incubation of AuNP-antibody conjugates with the sample on the detection area, the strip was rinsed three
22 times with the washing buffer to remove unbound conjugates and incubated with silver enhancement

23 solution from the Silver Enhancer Kit (Sigma-Aldrich Co. LLC). After 20min, the detection area was
24 rinsed with the washing buffer and air dried at room temperature.

1 **ELISA kit procedures.** The standard and serum samples were analyzed with 25-OH Vitamin D ELISA
2 kit (ALPCO Diagnostics) according to the provided protocol. Briefly, the samples were incubated with
3 the releasing agent to separate 25(OH)D molecules from DBP at 37°C for 1h. The samples and anti-
4 25(OH)D were then added onto the 25(OH)D coated microtiter plates. During an overnight (18-22h)
5 incubation, the 25(OH)D molecules in the sample and those immobilized on the plates competitively
6 bound to the available anti-25(OH)D. The plates were washed to remove any unbound anti-25(OH)D and
7 peroxidase-conjugated antibody were added to form 25(OH)D—anti-25(OH)D—peroxidase antibody
8 complex on the plate surface. After 1h incubation, the plates were washed and tetramethylbenzidine
9 (TMB) substrates were added which resulted in a reaction causing the solution color to change. After
10 20min, the reaction was stopped with an acidic solution and the absorption of the solution was measured
11 using Spectramax 384 at 450nm.

Acknowledgments

1 D.E. and S.M. acknowledge funding support through the Academic Venture Fund of the Atkinson Center
2 for a Sustainable Future at Cornell University. In addition, V.O. acknowledges the support of the National
3 Science and Engineering Research Council of Canada (NSERC) through a Postgraduate scholarship.
4 M.M. would like to acknowledge a National Science Foundation Graduate Research Fellowship under
5 Grant no. DGE-0707428. The fabrication steps described in this paper were carried out at the Cornell
6 Nanoscale Facility (CNF) and the Nanobiotechnology Center at Cornell University (NBTC).




Figure 1 a) vitaAID accessory on a iPhone with the inset showing the components of the accessory b) FT-IR spectra showing the chemical composition of the APTES, maleic anhydride and aminopropylated 25(OH)D₃ layers that constitute the detection area




Figure 2 a) Test strip and schematic of the gold nanoparticle-based immunoassay reaction on the detection area b) variation in predicted concentration at different AuNP-anti-25(OH)D₃ incubation times on the detection area for 0nM sample 25(OH)D




Figure 3 a) colorimetric variation on the test strip at different known 25(OH)D concentrations b) calibration curve showing brightness difference between the detection area and reference area ΔH at different known 25(OH)D concentrations c) algorithm used in quantifying 25(OH)D levels on test strip




Figure 4 a) predicted concentration vs. actual concentration (grey line) for calibration solutions at 15nM, 40nM and 110nM using vitaAID system (black) and ELISA kit (red) b) predicted concentrations of 25(OH)D in serum samples and comparison to the average ELISA result

Reference

1. M. F. Holick, *N Engl J Med*, 2007, 357, 266-281.
2. M. F. Holick, *The American Journal of Clinical Nutrition*, 2004, 79, 362-371.
3. T. J. Wang, M. J. Pencina, S. L. Booth, P. F. Jacques, E. Ingelsson, K. Lanier, E. J. Benjamin, R. B. D'Agostino, M. Wolf and R. S. Vasan, *Circulation*, 2008, 117, 503-511.
4. J. L. Anderson, H. T. May, B. D. Horne, T. L. Bair, N. L. Hall, J. F. Carlquist, D. L. Lappe and J. B. Muhlestein, *The American journal of cardiology*, 2010, 106, 963-968.
5. S. Mehta, E. Giovannucci, F. M. Mugusi, D. Spiegelman, S. Aboud, E. Hertzmark, G. I. Msamanga, D. Hunter and W. W. Fawzi, *PLoS ONE*, 2010, 5, e8770.
6. S. Mehta, D. J. Hunter, F. M. Mugusi, D. Spiegelman, K. P. Manji, E. L. Giovannucci, E. Hertzmark, G. I. Msamanga and W. W. Fawzi, *The Journal of infectious diseases*, 2009, 200, 1022-1030.
7. C. F. Garland, F. C. Garland, E. D. Gorham, M. Lipkin, H. Newmark, S. B. Mohr and M. F. Holick, *American Journal of Public Health*, 2006, 96, 252-261.
8. J. M. Lappe, D. Travers-Gustafson, K. M. Davies, R. R. Recker and R. P. Heaney, *The American Journal of Clinical Nutrition*, 2007, 85, 1586-1591.
9. M. XunWu, *Zhongguo Shiyong Neike Zazhi/Chinese Journal of Practical Internal Medicine*, 2009, 29, 965-967.
10. R. Chesney, *Rev Endocr Metab Disord*, 2001, 2, 145-151.
11. P. Lips, *J Steroid Biochem Mol Biol*, 2010, 121, 297-300.
12. A. Mithal, D. A. Wahl, J. P. Bonjour, P. Burckhardt, B. Dawson-Hughes, J. A. Eisman, G. El-Hajj Fuleihan, R. G. Josse, P. Lips and J. Morales-Torres, *Osteoporos Int*, 2009, 20, 1807-1820.
13. H. J. Roth, H. Schmidt-Gayk, H. Weber and C. Niederau, *Annals of clinical biochemistry*, 2008, 45, 153-159.
14. A. M. Wallace, S. Gibson, A. de la Hunty, C. Lamberg-Allardt and M. Ashwell, *Steroids*, 2010, 75, 477-488.
15. B. W. Hollis and R. L. Horst, *The Journal of Steroid Biochemistry and Molecular Biology*, 2007, 103, 473-476.
16. R. Gupta and S. Gupta, *Lateral flow immunoassay for detecting vitamins*, Report WO/2012/129650, 2012.
17. E. Fu, K. E. Nelson, S. A. Ramsey, J. O. Foley, K. Helton and P. Yager, *Anal Chem*, 2009, 81, 3407-3413.
18. P. Pradelles, J. Grassi, C. Creminon, B. Boutten and S. Mamas, *Anal Chem*, 1994, 66, 16-22.
19. K. Lei and Y. C. Butt, *Microfluid Nanofluid*, 2010, 8, 131-137.
20. C.-H. Yeh, C.-Y. Hung, T. Chang, H.-P. Lin and Y.-C. Lin, *Microfluid Nanofluid*, 2009, 6, 85-91.
21. Q. Wei, R. Nagi, K. Sadeghi, S. Feng, E. Yan, S. J. Ki, R. Caire, D. Tseng and A. Ozcan, *ACS nano*, 2014.
22. A. F. Coskun, R. Nagi, K. Sadeghi, S. Phillips and A. Ozcan, *Lab on a Chip*, 2013, 13, 4231-4238.
23. A. F. Coskun, J. Wong, D. Khodadadi, R. Nagi, A. Tey and A. Ozcan, *Lab on a Chip*, 2013, 13, 636-640.
24. V. Oncescu, M. Mancuso and D. Erickson, *Lab on a Chip*, 2014, 14, 759-763.
25. V. Oncescu, D. O'Dell and D. Erickson, *Lab on a Chip*, 2013, 13, 3232-3238.
26. J. H. Wang, L. P. Zhu, B. K. Zhu and Y. Y. Xu, *J Colloid Interface Sci*, 2011, 363, 676-681.
27. G. C. Chitanu, I. Popescu and A. Carpov, *Revue Roumaine de Chimie*, 2006, 51, 923-929.
28. J.-H. Jeong, Y.-S. Byoun and Y.-S. Lee, *Reactive and Functional Polymers*, 2002, 50, 257-263.
29. R.-H. Lin and J.-H. Hsu, *Polymer international*, 2001, 50, 1073-1081.

30. J. Kai, A. Puntambekar, N. Santiago, S. H. Lee, D. W. Sehy, V. Moore, J. Han and C. H. Ahn, *Lab on a Chip*, 2012, 12, 4257-4262.
31. J. Bigun, in *Vision with Direction: A Systematic Introduction to Image Processing and Computer Vision*, Springer, Germany, 2006, ch. 2, pp. 31-32.
32. C. S. Højskov, L. Heickendorff and H. J. Møller, *Clinica Chimica Acta*, 2010, 411, 114-116.
33. A. M. Wootton, *Clinical Biochemist Reviews*, 2005, 26, 33.
34. G. D Carter, *Current drug targets*, 2011, 12, 19-28.
35. A. C. Grodzki and E. Berenstein, in *Immunocytochemical Methods and Protocols*, Springer, 2010, pp. 15-26.
36. J. Ljungblad, Linköping University, Department of Physics, Chemistry and Biology, 2009.
37. M. Tasso, A. L. Cordeiro, K. Salchert and C. Werner, *Macromolecular bioscience*, 2009, 9, 922-929.
38. A. L. Cordeiro, T. Pompe, K. Salchert and C. Werner, in *Bioconjugation Protocols*, Springer, 2011, pp. 465-476.